2.8165
price up icon4.12%   0.1465
 
loading
前日終値:
$2.67
開ける:
$2.64
24時間の取引高:
14,400
Relative Volume:
0.35
時価総額:
$8.09M
収益:
-
当期純損益:
$-29.77M
株価収益率:
-2.7886
EPS:
-1.01
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
-10.03%
1か月 パフォーマンス:
+4.12%
6か月 パフォーマンス:
-43.95%
1年 パフォーマンス:
-64.51%
1日の値動き範囲:
Value
$2.63
$2.84
1週間の範囲:
Value
$2.47
$3.18
52週間の値動き範囲:
Value
$2.115
$15.75

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
名前
Moleculin Biotech Inc
Name
セクター
Healthcare (1195)
Name
電話
713-300-5160
Name
住所
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
職員
18
Name
Twitter
@moleculinbio
Name
次回の収益日
2024-12-08
Name
最新のSEC提出書
Name
MBRX's Discussions on Twitter

MBRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
MBRX 2.795 8.09M 0 -29.77M -24.23M -1.01
VRTX 449.44 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.00 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.25 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.03 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.90 24.89B 3.30B -501.07M 1.03B 11.54

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-07-18 再開されました Oppenheimer Outperform

Moleculin Biotech Inc (MBRX) 最新ニュース

pulisher
01:47 AM

Financial Comparison: Moleculin Biotech (NASDAQ:MBRX) & RedHill Biopharma (NASDAQ:RDHL) - Defense World

01:47 AM
pulisher
Nov 20, 2024

Moleculin Biotech Corporate Presentation Posted on Company WebsiteOn November 18, 2024, Moleculin Biotech, Inc. made public a corporate presentation on its official website. This presentation, identified as Exhibit 99.1 in the Current Report on Form - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

What is Roth Capital’s Forecast for MBRX Q1 Earnings? - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Moleculin Biotech Unveils New Corporate Presentation - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PR Newswire

Nov 18, 2024
pulisher
Nov 17, 2024

Moleculin Biotech Amends Clinical Trial Protocol for Phase 3 Trial - Defense World

Nov 17, 2024
pulisher
Nov 15, 2024

Armistice Capital, LLC Expands Portfolio with Moleculin Biotech Inc Acquisition - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Moleculin (MBRX) Stock Jumps On Accelerated Clinical Trial News - Stocks Telegraph

Nov 15, 2024
pulisher
Nov 14, 2024

Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Pivotal Trial to H2 2025 - Marketscreener.com

Nov 14, 2024
pulisher
Nov 14, 2024

Moleculin Biotech advances Annamycin AML trial protocol - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Moleculin Biotech Accelerates Annamycin Phase 3 Trial - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 - PR Newswire

Nov 14, 2024
pulisher
Nov 14, 2024

Maxim Group Has Lowered Expectations for Moleculin Biotech (NASDAQ:MBRX) Stock Price - Defense World

Nov 14, 2024
pulisher
Nov 12, 2024

Moleculin Biotech Reports Financial Highlights and Future Plans - Yahoo Finance

Nov 12, 2024
pulisher
Nov 12, 2024

Moleculin gets IRB nod for Phase 3 AML trial - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 12, 2024
pulisher
Nov 12, 2024

Moleculin gets IRB nod for Phase 3 AML trial By Investing.com - Investing.com Nigeria

Nov 12, 2024
pulisher
Nov 12, 2024

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PR Newswire

Nov 12, 2024
pulisher
Nov 11, 2024

Earnings call: Moleculin Biotech optimistic on Annamycin's trial By Investing.com - Investing.com Australia

Nov 11, 2024
pulisher
Nov 11, 2024

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Nov 11, 2024
pulisher
Nov 08, 2024

Moleculin Biotech Inc. (MBRX) Quarterly 10-Q Report - Quartz

Nov 08, 2024
pulisher
Nov 08, 2024

Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 07, 2024

Moleculin Biotech (MBRX) Set to Announce Quarterly Earnings on Friday - Defense World

Nov 07, 2024
pulisher
Nov 05, 2024

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - StreetInsider.com

Nov 05, 2024
pulisher
Nov 05, 2024

Moleculin Biotech : to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast Form 8 K - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com - Defense World

Nov 05, 2024
pulisher
Nov 04, 2024

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin - Star Local Media

Nov 04, 2024
pulisher
Oct 30, 2024

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML - GuruFocus.com

Oct 30, 2024
pulisher
Oct 28, 2024

Soft Tissue Sarcoma Market Growth to Accelerate in Forecast - openPR

Oct 28, 2024
pulisher
Oct 28, 2024

Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com - Defense World

Oct 28, 2024
pulisher
Oct 26, 2024

Moleculin Biotech stockholders approve new stock plan By Investing.com - Investing.com South Africa

Oct 26, 2024
pulisher
Oct 26, 2024

Moleculin to Participate in the Virtual Investor Lunch Break: Th - GuruFocus.com

Oct 26, 2024
pulisher
Oct 26, 2024

Moleculin Abstract Accepted for Poster Presentation at the Europ - GuruFocus.com

Oct 26, 2024
pulisher
Oct 25, 2024

Moleculin Biotech stockholders approve new stock plan - Investing.com India

Oct 25, 2024
pulisher
Oct 25, 2024

Moleculin Biotech’s Annual Meeting Decisions and Elections - TipRanks

Oct 25, 2024
pulisher
Oct 19, 2024

Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World

Oct 19, 2024
pulisher
Oct 18, 2024

Moleculin Biotech Highlights Annamycin’s AML Treatment Potential - Yahoo Finance

Oct 18, 2024
pulisher
Oct 17, 2024

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - Financial Times

Oct 17, 2024
pulisher
Oct 14, 2024

Ependymoma Market to Rise by 2032, DelveInsight | Fera - openPR

Oct 14, 2024
pulisher
Oct 12, 2024

StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World

Oct 12, 2024
pulisher
Oct 09, 2024

Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: P - GuruFocus.com

Oct 09, 2024
pulisher
Oct 07, 2024

Moleculin Announces Proposed Underwritten Public Offering - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Moleculin Announces Full Exercise of Over-Allotment Option - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 - Marketscreener.com

Oct 07, 2024
pulisher
Oct 04, 2024

Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Moleculin to Present at Two Upcoming Investor Conferences - Marketscreener.com

Oct 04, 2024
pulisher
Oct 04, 2024

Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Moleculin to Present at Two Upcoming Investor Conferences – Company Announcement - Financial Times

Oct 04, 2024
pulisher
Oct 02, 2024

Moleculin Biotech Releases Updated Corporate Presentation - TipRanks

Oct 02, 2024

Moleculin Biotech Inc (MBRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):